The Technical AnalystExchange: STO Sector: Healthcare Industry: Medical Care Facilities
ProstaLund AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.39% SEK0.654
America/New_York / 17 mai 2024 @ 11:11
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 50.09 mill |
| EPS: | -0.250 |
| P/E: | -2.62 |
| Earnings Date: | May 16, 2024 |
| SharesOutstanding: | 76.59 mill |
| Avg Daily Volume: | 0.130 mill |
| RATING 2024-05-17 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.62 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -2.62 | industry: PE 63.35 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
SEK 0.540 - 0.768 ( +/- 17.43%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK0.654 (-4.39% ) |
| Volume | 0.238 mill |
| Avg. Vol. | 0.130 mill |
| % of Avg. Vol | 182.98 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PLUN.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PLUN.ST
ProstaLund AB (publ) develops and sells urological devices for the treatment of patients with benign prostatic hyperplasia (BPH) in Sweden and internationally. The company also offers CoreTherm, a heat treatment of BPH; and Gepan instill for the treatment of chronic bladder inflammation. Its products are used in hospitals and clinics. The company was founded in 1991 and is based in Lund, Sweden. ProstaLund AB (publ) is a subsidiary of Farstorps Gard Forvaltnings AB.